| Date | Title | Description |
| 09.04.2026 | Patients for Bitopertin Launches, Calls for Urgent Path Forward After FDA Delays Approval Decision | With EPP and XLP, painful reactions to sunlight can begin within minutes of sun exposure
Patients for Bitopertin
Before and after starting bitopertin, EPP patient Craig Leppert can now spend time in the sun without pain.
New patient-driven ... |
| 06.03.2026 | FDA reversals leave investors worrying about the fates of other experimental drugs | The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna’s flu shot before reversing course.
Companies have accused the FDA of ... |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 08.12.2024 | Atlas Venture: $450 Million Fund XIV Closed To Invest In Biotech Innovation | Atlas Venture—a leading early-stage venture capital firm investing in biotech innovation—announced closing its fourteenth fund, raising $450 million in an oversubscribed fundraise. Through Fund XIV, Atlas Venture will continue collaborating... |
| 08.11.2024 | Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. | Facility significantly increases future financial and operational flexibilityUp to $200M available, with $30 million drawn at close and additional $80 million available at Disc’s sole discretion through second-half 2026Funding can support d... |
| 08.11.2024 | Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. | Facility significantly increases future financial and operational flexibility Up to $200M available, with $30 million drawn at close and additional $80 million available at Disc’s sole discretion through second-half 2026 Funding can support... |
| 14.02.2023 | Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs | - |
| 14.02.2023 | Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs | - |
| 20.01.2023 | $412.5 million! Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases | SAN DIEGO, Jan. 20, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced its wholly-owned subsidiary Mabwell Therapeutics has entered into an agreement with DIS... |
| 07.09.2021 | Digital health news, funding roundup in the prior week; September 6 | Whoop raised $200M and acquired PUSH; Cityblock landed $400M; Eight Sleep secured $86M
Push: Push is a personalized digital fitness and health coach. Whoop acquired PUSH for an undisclosed amount. Whoop makes a wearable that monitors sleep ... |
| 04.09.2021 | Daily funding roundup - September 3th, 2021 | Disc Medicine raised $90M; Centaur Labs secured $15M; SimpliFed landed $500K
Disc Medicine: Disc Medicine is a Cambridge, Ma.-based clinical-stage biotech focused on hematologic diseases. Disc Medicine raised $90 million in Series B funding... |
| 03.09.2021 | The unsexy part of ESG investing | “Esg” sounds more like a noise investors would have made two years ago when hearing the term ESG: The acronym for environmental, social, and governance factors used to determine whether a company is operating ethically.
Paid Content How to ... |
| 03.09.2021 | The unsexy part of ESG investing | “Esg” sounds more like a noise investors would have made two years ago when hearing the term ESG: The acronym for environmental, social, and governance factors used to determine whether a company is operating ethically.
Now though, interest... |
| 03.09.2021 | Disc Medicine Nets $90M Series B Financing |
CAMBRIDGE, MA, Disc Medicine, a clinical-stage biotechnology company, announced a $90 million Series B financing.
>> Click here for more funding data on Disc Medicine
>> To export Disc Medicine funding data to PDF and Excel,... |
| 02.09.2021 | Blood disorder biotech Disc Medicine gets $90M to bring two drugs into Phase 2 | The rare diseases called erythropoietic porphyrias (EP) show up in the blood, but patients feel them most acutely on the skin. Light sensitivity is a major symptom of these enzyme deficiencies affecting red blood cells, and sunlight can cau... |
| 02.09.2021 | Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases | |
| 02.09.2021 | Disc Medicine Raises $90M in Series B Funding | Disc Medicine, a Cambridge MA-based biotechnology company, raised $90M in Series B funding.
The round was led by OrbiMed with participation from new investors Arix Bioscience, Janus Henderson Investors, 5AM Ventures, Rock Springs Capital, N... |
| 02.09.2021 | Disc Medicine nabs $90M for blood disease pipeline, new Roche asset | Disc Medicine has raised $90 million in a series B round as it looks to push on with its pipeline of early- to midstage blood disorder assets.
Upcoming Conference Join the world’s top medtech executives for the leading industry event – in-p... |
| 02.09.2021 | Disc Medicine nabs $90M for blood disease pipeline, new Roche asset | Disc Medicine has raised $90 million in a series B round as it looks to push on with its pipeline of early- to midstage blood disorder assets.
The latest cash drop will be used toward its lead phase 2 program bitopertin, an oral GlyT1 inhib... |
| 02.09.2021 | Disc Medicine, Inc. announced that it has received $90 million in funding from a group of investors | Disc Medicine, Inc. announced that it has raised $90 million in a round of funding led by new investor, OrbiMed Advisors LLC on September 2, 2021. The transaction also included participation from other new investors, Arix Bioscience plc for... |
| 02.09.2021 | Disc Medicine : Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases | CAMBRIDGE, Mass., Sept. 2, 2021 /PRNewswire/ -- Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for the treatment of serious and debilitating hematologic diseases, today an... |
| 23.08.2021 | Disc Medicine Appoints Will Savage, MD, PhD as Chief Medical Officer and Jonathan Yu as Chief Business Officer and Expands Scientific Leadership with Key Hires to Advance Clinical-Stage Pipeline | |
| 27.05.2021 | Disc Medicine Expands Hematology Pipeline with Worldwide Licensing Agreement for Bitopertin, a First-in-Class Modulator of Heme Synthesis | |
| 13.10.2020 | Disc Medicine Expands Scientific Advisory Board with Leading Experts in Hepcidin Biology | |
| 30.10.2019 | Disc Medicine Raises $50M in Series A Financing | Disc Medicine, a Cambridge, Mass.-based hematology company, completed a $50m Series A financing.
The round was led by Novo Holdings A/S along with Access Biotechnology and founding investor Atlas Venture. Donald Nicholson, former CEO of Nim... |
| 29.10.2019 | Disc Medicine Completes $50 Million Series A Financing | Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases, today announced the completion of a $50 million Series A financing. The compa... |
| - | Blood disorder biotech Disc Medicine gets $90M to bring two drugs into Phase 2 | The rare diseases called erythropoietic porphyrias (EP) show up in the blood, but patients feel them most acutely on the skin. Light sensitivity is a major symptom of these enzyme deficiencies affecting red blood cells, and sunlight can cau... |
